Publication Name	World Journal of Clinical Oncology
Manuscript ID	20645
Country	Spain

Received	2015-06-15 08:40
Peer-Review Started	2015-06-16 17:18
To Make the First Decision	2015-09-16 09:12
Return for Revision	2015-09-22 16:30
Revised	2015-09-24 03:28
Second Decision	2015-11-09 10:57
Accepted by Journal Editor-in-Chief	2015-11-09 13:51
Accepted by Executive Editor-in-Chief	2015-12-18 16:50
Articles in Press	2015-12-18 16:50
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-03-23 13:48
Publish the Manuscript Online	2016-04-07 11:01

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?
Manuscript Source	Invited Manuscript
All Author List	Enrique Grande
Funding Agency and Grant Number
Corresponding Author	Enrique Grande, MD, Department of Medical Oncology, Ramón y Cajal University Hospital, Carretera de Colmenar Km 9, 1, 28034 Madrid, Spain. egrande@oncologiahrc.com
Key Words	Carcinoids; Everolimus; Neuroendocrine tumors; Pancreas; Overcoming resistance; Sequential-treatment; Sunitinib
Core Tip	There is a need to improve the rationale we use when approaching to a sequential systemic treatment strategy in disseminated neuroendocrine tumors. Up to now, we do not have level 1 evidence to use any systemic alternative after failure to a prior one. Widely heterogeneous populations have been recruited in larger phase Ⅲ pivotal trials in neuroendocrine tumors. Therefore, it is difficult to find final conclusions from the registration trials. In this article we aim to summarize the available evidence behind the use of different alternatives after failure to standard somatostatin analogs.
Publish Date	2016-04-07 11:01
Citation	Grande E. Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale? World J Clin Oncol 2016; 7(2): 149-154
URL	http://www.wjgnet.com/2218-4333/full/v7/i2/149.htm
DOI	http://dx.doi.org/10.5306/wjco.v7.i2.149

Full Article (PDF)	WJCO-7-149.pdf
Full Article (Word)	WJCO-7-149.doc
Manuscript File	20645-Review.docx
Answering Reviewers	20645-Answering reviewers.pdf
Audio Core Tip	20645-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	20645-Conflict-of-interest statement.pdf
Copyright License Agreement	20645-Copyright assignment.pdf
Peer-review Report	20645-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	20645-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	20645-Scientific misconduct check.pdf
Scientific Editor Work List	20645-Scientific editor work list.pdf